Medeon Biodesign (6499) — Capital Reinvestment Ratio

Latest as of March 2022: 0.68x

Medeon Biodesign (6499) has a Capital Reinvestment Ratio of 0.68x as of March 2022, meaning it reinvests 1% of its operating cash flow (NT$60.74 Million) in capital expenditures (NT$41.12 Million). See 6499 net asset quality score to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.68x
Capex / Operating Cash Flow

Operating Cash Flow

NT$60.74 Million
TWD

Capital Expenditures

NT$41.12 Million
TWD

Data as of

Mar 2022
Most recent filing

Medeon Biodesign Capital Reinvestment Ratio (2018–2018)

This chart tracks Medeon Biodesign's Capital Reinvestment Ratio across 1 annual periods. Check 6499 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Medeon Biodesign (2018–2018)

Year-by-year Capital Reinvestment Ratio for Medeon Biodesign from 2018 to 2018. For live market cap and broader valuation context, see how much is Medeon Biodesign worth.

Year Reinvestment Ratio Operating CF (TWD) Capital Expenditures YoY Change
2018 0.16x NT$322.05 Million NT$51.14 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow